Veracyte‘s patent involves a method to differentiate between usual interstitial pneumonia (UIP) and non-UIP using gene markers like MPO, GGNBP2, SELE, and many more. By assaying lung tissue samples, the method accurately classifies the presence of UIP. GlobalData’s report on Veracyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Veracyte, ML-based biomarker screening was a key innovation area identified from patents. Veracyte's grant share as of May 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Method for identifying usual interstitial pneumonia (uip) or non-uip
A recently granted patent (Publication Number: US11976329B2) outlines a method for identifying whether a subject has usual interstitial pneumonia (UIP) or non-usual interstitial pneumonia (non-UIP). The method involves pooling lung tissue samples from the subject, assaying the pooled sample for the expression levels of specific genes associated with UIP or non-UIP, processing this data to classify the sample, and outputting the classification. The classification accuracy is claimed to be at least 90%, with a trained algorithm used for processing, potentially incorporating smoking status as a covariate and various genetic features for analysis.
Furthermore, the method allows for the detection of additional markers associated with smoker status bias, with a weighted algorithm applied to differentiate these markers. The patent also covers the use of pooled epithelium samples, cytologically ambiguous samples, and the inclusion of multiple genes as markers for classification. The classification generated by the method is claimed to have a specificity of at least 90% and a sensitivity of at least 70%, with non-UIP conditions including hypersensitivity pneumonitis, nonspecific interstitial pneumonia, and others. Overall, the patent details a comprehensive approach to identifying UIP and non-UIP based on gene expression analysis in lung tissue samples, potentially offering a high level of accuracy in diagnosis.
To know more about GlobalData’s detailed insights on Veracyte, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
